BioSpace News Archive

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders

Application of comfortable and functional waveform to relieve pain associated with temporomandibular joint dysfunction.

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that Jon Wigginton, M.D. is stepping down from his day-to-day role as Chief Medical Officer, and will assume the role of Chairman of the company’s Scientific Advisory Board (SAB) and Senior Advisor to the CEO.

– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization – –

The University of Pittsburgh’s Rehab Neural Engineering Labs demonstrate improved and faster grasping ability with artificial tactile feedback using Blackrock Neurotech’s NeuroPort System to restore function: Move Again and Feel Again.

Kiromic is pleased to announce the identification of new targets for the treatment of solid tumors, identified through the application of its bioinformatics platform

Université de Sherbrooke and KEY DH Technologies Inc. subsidiary deutraMed Inc. announced a collaboration to accelerate the development of deutraMed’s innovative Biomolecule Stabilization Technology platform.

Regulus Therapeutics Inc. today announced an incremental update from the first cohort of patients with ADPKD in its ongoing Phase 1b clinical trial of RGLS4326.

– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus (P=0.004) primary endpoints, with a diarrhea rate of 10% vs 5% placebo – – Integrated EU commercial, access and medical organization in place ready to launch following EU marketing authorization –

Lantheus Holdings Announces Presentation Featuring 18 F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting